TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Dating Sites: Best, Worst & Weirdest
TECHNOLOGY

Excited? Don't Be. It's Reverse-Split Time

  • By George Mannes
  • Jun 18, 2001 6:49 PM EDT
PRESS RELEASES

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day With Launch Of Disease Awareness Campaign

  • By Business Wire
  • Jan 24, 2021 9:00 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces First Patient Enrolled In Phase 2b VISTAS Clinical Study Evaluating Volixibat In Adult Patients With Primary Sclerosing Cholangitis

  • By Business Wire
  • Jan 14, 2021 9:00 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Provides Corporate Update

  • By Business Wire
  • Jan 12, 2021 9:00 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Jan 8, 2021 6:17 PM EST
PRESS RELEASES

Mirum Pharmaceuticals To Present At The 39th Annual J.P. Morgan Healthcare Conference On January 12, 2021

  • By Business Wire
  • Jan 4, 2021 8:30 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

  • By Business Wire
  • Dec 14, 2020 9:00 PM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces Commencement Of Public Offering Of Common Stock

  • By Business Wire
  • Dec 14, 2020 7:00 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Dec 10, 2020 7:41 PM EST
PRESS RELEASES

Mirum Pharmaceuticals And Oberland Capital Announce Up To $210 Million Funding Arrangement

  • By Business Wire
  • Dec 9, 2020 9:00 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces European Medicines Agency Validation Of The Marketing Authorization Application For Maralixibat In Patients With PFIC2

  • By Business Wire
  • Nov 30, 2020 8:30 AM EST
PRESS RELEASES

Mirum Pharmaceuticals To Present At Upcoming Investor Conferences

  • By Business Wire
  • Nov 23, 2020 9:30 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements In Pruritus And Quality Of Life In Children With Alagille Syndrome Treated With Maralixibat

  • By Business Wire
  • Nov 15, 2020 6:00 PM EST
PRESS RELEASES

Mirum Pharmaceuticals Presents New Data From Its Maralixibat And Volixibat Clinical Studies At AASLD Annual Meeting

  • By Business Wire
  • Nov 13, 2020 8:10 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Nov 10, 2020 7:00 PM EST
PRESS RELEASES

Mirum Pharmaceuticals Broadens Expanded Access Program For Maralixibat In Alagille Syndrome To Europe And Australia

  • By Business Wire
  • Nov 5, 2020 8:30 AM EST
PRESS RELEASES

Mirum Pharmaceuticals Announces New Data Being Presented In Late-Breaker Oral And Poster Presentations At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

  • By Business Wire
  • Nov 2, 2020 8:30 AM EST
PRESS RELEASES

Mirum Pharmaceuticals To Present Maralixibat Data And Host Symposium At The NASPGHAN Annual Meeting 2020

  • By Business Wire
  • Oct 26, 2020 8:30 AM EDT
PRESS RELEASES

Mirum Pharmaceuticals Announces Partnership With EVERSANA To Support Launch And Commercialization Of Maralixibat For Alagille Syndrome In The United States

  • By PR Newswire
  • Oct 15, 2020 8:55 AM EDT
PRESS RELEASES

Mirum Pharmaceuticals Announces Partnership With EVERSANA To Support Launch And Commercialization Of Maralixibat For Alagille Syndrome In The United States

  • By Business Wire
  • Oct 15, 2020 8:45 AM EDT
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Oct 13, 2020 4:05 PM EDT
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Sep 11, 2020 4:30 PM EDT
PRESS RELEASES

Mirum Pharmaceuticals To Present At Investor Conferences In September

  • By Business Wire
  • Sep 11, 2020 7:00 AM EDT
PRESS RELEASES

(Graphic: Business Wire)

  • By Business Wire
  • Aug 29, 2020 8:45 AM EDT
PRESS RELEASES

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By Business Wire
  • Aug 11, 2020 5:30 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.